• Zai Lab posted a U.S. GAAP net loss of USD 101.8 million, widening 14%, as revenue fell 5% to USD 205.9 million.
• Net product revenue slipped 6% to USD 201.3 million; ZEJULA dropped 31% to USD 62 million, VYVGART fell 7% to USD 41.4 million.
• XACDURO more than doubled to USD 16.5 million; NUZYRA rose 13% to USD 33.4 million, partially offsetting declines.
• R&D expenses climbed 14% to USD 127.4 million due to higher licensing fees; operating loss widened 31% to USD 145.9 million.
• KarXT launched in mainland China in June 2026; cash, cash equivalents, restricted cash totaled USD 708.6 million at June 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299364), on August 25, 2026, and is solely responsible for the information contained therein.